[The drug "Selena" in the complex treatment of patients with chronic inflammatory diseases of the biliary system].
The drug selena of the Novamed firm has been shown to be of high clinical, biochemical, and immunological effectiveness in a combined treatment of patients with chronic inflammatory diseases of the biliary system presenting with immunological disorders, that was evidenced by a sooner than in controls disappearance or alleviation of clinical manifestations of the disease, normalization of clinical indices for blood, ultrastructure of the immunocompetent cells, and by less time for the functional state of the liver to return to normal. It is suggested that the drug effect on the immune system might be mediated through normalization of lipid peroxidation and of the system for antioxidant defence.
Iepishyn
A V
AV
Khabarova
N A
NA
Chernets'
T Iu
TIu
Kuz'mych
Iu P
IuP
D000328:Adult; D000917:Antibody Formation / Q000187:drug effects*; D000975:Antioxidants / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology / Q000648:ultrastructure; D002764:Cholecystitis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D006505:Hepatitis / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D012643:Selenium / Q000627:therapeutic use*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology / Q000648:ultrastructure; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000648:ultrastructure
D000975:Antioxidants; D012643:Selenium